Cellectar Biosciences

Yahoo Finance • 14 days ago

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

FLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and develo... Full story

Yahoo Finance • 16 days ago

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention... Full story

Yahoo Finance • 20 days ago

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today annou... Full story

Yahoo Finance • 22 days ago

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today annou... Full story

Yahoo Finance • 29 days ago

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

FLORHAM PARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announ... Full story

Yahoo Finance • last month

Cellectar Biosciences GAAP EPS of -$3.39 beats by $0.31

* Cellectar Biosciences press release [https://seekingalpha.com/pr/20200781-cellectar-biosciences-reports-second-quarter-2025-financial-results-and-provides-a-corporate] (NASDAQ:CLRB [https://seekingalpha.com/symbol/CLRB]): Q2 GAAP EPS o... Full story

Yahoo Finance • last month

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway C... Full story

Yahoo Finance • 2 months ago

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of c... Full story

Yahoo Finance • 3 months ago

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of canc... Full story

Yahoo Finance • 3 months ago

Cellectar Biosciences prices $6 million public offering

FLORHAM PARK, N.J. - Cellectar Biosciences, Inc. (NASDAQ:CLRB), currently valued at $9.1 million in market capitalization, has priced an underwritten public offering expected to generate approximately $6 million in gross proceeds before de... Full story

Yahoo Finance • 3 months ago

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of canc... Full story

Yahoo Finance • 3 months ago

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST... Full story

Yahoo Finance • 3 months ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Cellectar B... Full story

Yahoo Finance • 3 months ago

Cellectar Biosciences announces one-for-thirty reverse stock split

* Cellectar Biosciences (NASDAQ:CLRB [https://seekingalpha.com/symbol/CLRB]) announced on Wednesday a one-for-thirty reverse stock split of the company’s common stock, effective at 12:01 a.m. Eastern Time on Tuesday, June 24, 2025. * T... Full story

Yahoo Finance • 3 months ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announ... Full story

Yahoo Finance • 3 months ago

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

FLORHAM PARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announ... Full story

Yahoo Finance • 4 months ago

Cellectar Biosciences enters into common stock agreements to raise $2.5 million

* Cellectar Biosciences (NASDAQ:CLRB [https://seekingalpha.com/symbol/CLRB]) announced on Thursday the entry into definitive agreements to raise $2.5 million from the sale of shares of the company’s common stock priced at-market for Nasd... Full story

Yahoo Finance • 4 months ago

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0% Compa... Full story

Yahoo Finance • 5 months ago

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of ca... Full story

Yahoo Finance • 6 months ago

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) Evaluating timing for Phase 1 solid tumor stud... Full story